AbbVie Inc. Gross Margin

Gross Margin of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending December 30, 2019 was 76.95% (a -0.53% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -1.8%
  • Annual Gross Margin for 2019 was 77.64% (a 1.57% increase from previous year)
  • Annual Gross Margin for 2018 was 76.44% (a 1.87% increase from previous year)
  • Annual Gross Margin for 2017 was 75.04% (a -2.86% decrease from previous year)
  • Twelve month Gross Margin ending December 30, 2019 was 77.64% (a 0.41% increase compared to previous quarter)
  • Twelve month trailing Gross Margin increased by 0.74% year-over-year
Trailing Gross Margin for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
77.64% 77.32% 77.41% 77.07%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of AbbVie Inc.

Most recent Gross Marginof ABBV including historical data for past 10 years.

Interactive Chart of Gross Margin of AbbVie Inc.

AbbVie Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 76.95% 77.36% 77.96% 78.36% 77.64%
2018 75.65% 77.72% 76.64% 75.71% 76.44%
2017 70.53% 76.9% 77.98% 75.28% 75.04%
2016 77.13% 76.62% 78.22% 77.02% 77.25%
2015 76.95% 80.37% 83.27% 81.31% 80.31%
2014 79.48% 78.2% 77.41% 75.89% 77.83%
2013 74.92% 76.56% 77.54% 73.37% 75.62%
2012 75.7% 77.51% 76.12% 72.3% 75.47%
2011 29.45% 100.0% 100.0% 69.02% 73.41%
2010 72.55%
2009 71.46%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.